Today's Top Gainer
Note:Top Gainer - Nifty 50 More
SPARC is awaiting USFDA approval on its late stage innovative drugs, Elepsia (Epilepsy drug) and Xelpros (Glaucoma drug). Both ...
Accumulate Reco. Price: 383.95
Company operates an asset light model with lowest capital cost per operational bed than peers (Rs28lakh per bed in Q2FY18). We ...
Accumulate Reco. Price: 244.60